Trial: Surpass Et

Current treatment approaches in ET and an insight into the SURPASS-ET trial

VJHemOnc – Video Journal of Hematology & HemOnc

SURPASS ET: P1101 in essential thrombocythemia

VJHemOnc – Video Journal of Hematology & HemOnc

SURPASS ET: ropeginterferon versus anagrelide as second line therapy in essential thrombocythemia

VJHemOnc – Video Journal of Hematology & HemOnc

SURPASS ET: ropeginterferon alfa-2b vs anagrelide for second-line essential thrombocythemia

VJHemOnc – Video Journal of Hematology & HemOnc

The SURPASS-ET study: evaluating novel treatment approaches in ET

VJHemOnc – Video Journal of Hematology & HemOnc

Frias_Tirzepatide: Overview of SURPASS Trials in Patients With Type 2 Diabetes

Cardiometabolic Health Congress (CMHC)

EXCEED-ET: ropeginterferon alfa-2b in adults with essential thrombocythemia

VJHemOnc – Video Journal of Hematology & HemOnc

Update on Adaptimmune's SURPASS Family of Trials

Adaptimmune Therapeutics

Expert commentary: The EXCEED trial | Laura Coates

Medicine Matters rheumatology

De Havilland Mosquito - Early Development of the "Wooden Wonder"

Lucia Masarova, MD, Discusses EXCEED-ET Trial Design, Enrollment Process

Blood Cancers Today

The SURPASS Trials on Tirzepatide: Single Agent Data and Comparison to Semaglutide

The SURPASS Trials on Tirzepatide: Analysis and Clinical Outlook

Essential Thrombocythemia: What Patients Should Know (2022) | Top MPN Specialist Dr. Ruben Mesa

The Patient Story

Researcher comment: The EXCEED trial | Frank Behrens

Medicine Matters rheumatology

LeBron James ADMITS that Michael Jordan IS THE GOAT - 2023

CroPETROforeverNBA

Final analysis of the phase 4 EXELS trial in high-risk patients with essential thrombocythemia

VJHemOnc – Video Journal of Hematology & HemOnc

ACC.24: The SMART Trial

Radcliffe Cardiology

PROVE THEM WRONG - Motivational Speech

Ben Lionel Scott

How NOT to Conduct a Randomized Clinical Trial